- Home
- DRH vs VRDN Comparison
DRH vs VRDN Comparison
Compare DRH & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRH
- VRDN
- Stock Information
- Founded
- DRH 2004
- VRDN 2006
- Country
- DRH United States
- VRDN United States
- Employees
- DRH N/A
- VRDN N/A
- Industry
- DRH Real Estate Investment Trusts
- VRDN Medical Specialities
- Sector
- DRH Real Estate
- VRDN Health Care
- Exchange
- DRH Nasdaq
- VRDN Nasdaq
- Market Cap
- DRH 1.4B
- VRDN 1.6B
- IPO Year
- DRH 2005
- VRDN N/A
- Fundamental
- Price
- DRH $7.20
- VRDN $13.50
- Analyst Decision
- DRH Hold
- VRDN Buy
- Analyst Count
- DRH 6
- VRDN 12
- Target Price
- DRH $9.17
- VRDN $36.44
- AVG Volume (30 Days)
- DRH 3.0M
- VRDN 1.1M
- Earning Date
- DRH 05-01-2025
- VRDN 05-07-2025
- Dividend Yield
- DRH 5.15%
- VRDN N/A
- EPS Growth
- DRH N/A
- VRDN N/A
- EPS
- DRH 0.18
- VRDN N/A
- Revenue
- DRH $1,129,883,000.00
- VRDN $302,000.00
- Revenue This Year
- DRH $1.34
- VRDN N/A
- Revenue Next Year
- DRH $2.45
- VRDN $20,553.29
- P/E Ratio
- DRH $39.89
- VRDN N/A
- Revenue Growth
- DRH 5.12
- VRDN N/A
- 52 Week Low
- DRH $6.19
- VRDN $9.90
- 52 Week High
- DRH $10.00
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DRH 47.22
- VRDN 49.53
- Support Level
- DRH $6.82
- VRDN $9.90
- Resistance Level
- DRH $7.40
- VRDN $14.61
- Average True Range (ATR)
- DRH 0.38
- VRDN 1.07
- MACD
- DRH 0.06
- VRDN 0.28
- Stochastic Oscillator
- DRH 83.47
- VRDN 76.43
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.